HAWAII CELLULAR THERAPY AND TRANSP… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2014

Legal Domicile

Principal Officer

RANDAL WADA

Phone

8085476332

Tax Period

2023-07-01 to 2024-06-30

HAWAII CELLULAR THERAPY AND TRANSPLANT LABORATORY, founded in 2014, is a small nonprofit in the Medical Research sector that reported $258K in total revenue in fiscal year 2023. Revenue grew 10% year-over-year, indicating healthy expansion. Expenses of $520K exceeded revenue, resulting in a 102% operating deficit.

Mission

TO FACILITATE AND SUPPORT CELLULAR THERAPY AND TRANSPLANT SERVICES FOR THE PATIENTS OF HAWAII AND THE PACIFIC

Program Service Accomplishments

Program 1

Expenses: $513,937 Revenue: $257,593

TO FACILITATE AND SUPPORT CELLULAR THERAPY AND TRANSPLANT SERVICES FOR THE PATIENTS OF HAWAII AND THE PACIFIC

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $0

Program Service Revenue $227,891

Investment Income $29,702

Other Revenue $0

TOTAL REVENUE $257,593

Expense Breakdown

Grants Paid $0

Salaries & Benefits $281,738

Fundraising Expenses $0

Program Expenses $513,937

Other Expenses $238,625

TOTAL EXPENSES $520,363

Year-over-Year Comparison

	2023	2022	Change
Revenue	$257,593	$234,533	+0.1%
Expenses	$520,363	$475,858	+0.1%
Net Income	$-262,770	$-241,325	+0.1%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✓ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$82,130

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
RAYDEEN M BUSSE	C/DIRECTOR	0.50	Director	$0	$0	$0
SIMON CHANG	VC/DIRECTOR	0.50	Director	$0	$0	$0
ROBERT COONEY	DIRECTOR	0.50	Director	$0	$0	$0
JAMES BENNETT	DIRECTOR	0.50	Director	$0	$0	$0
RANDAL WADA	PRES/CEO	10.00	Officer	$82,130	$0	$82,130

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	No data	No data	No data	No data
2024	$257,593	$520,363	$636,438	$-262,770
2023	$234,533	$475,858	$737,170	$-241,325
2022	$173,577	$446,729	$983,992	$-273,152
2021	$1,171,094	$1,112,326	$1,216,555	$58,768
2020	$2,448,135	$2,549,135	$1,393,316	$-101,000
2019	$2,350,349	$2,538,756	$1,287,438	$-188,407
2018	$2,352,244	$2,499,724	$1,499,779	$-147,480

HAWAII CELLULAR THERAPY AND TRANSPLANT LABORATORY